HUP0600226A3 - Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use - Google Patents
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical useInfo
- Publication number
- HUP0600226A3 HUP0600226A3 HU0600226A HUP0600226A HUP0600226A3 HU P0600226 A3 HUP0600226 A3 HU P0600226A3 HU 0600226 A HU0600226 A HU 0600226A HU P0600226 A HUP0600226 A HU P0600226A HU P0600226 A3 HUP0600226 A3 HU P0600226A3
- Authority
- HU
- Hungary
- Prior art keywords
- antidiabetic
- medical use
- conformationally constrained
- antiobesity agents
- analogs useful
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125708 antidiabetic agent Drugs 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29450501P | 2001-05-30 | 2001-05-30 | |
PCT/US2002/016628 WO2002096357A2 (en) | 2001-05-30 | 2002-05-23 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0600226A2 HUP0600226A2 (en) | 2006-11-28 |
HUP0600226A3 true HUP0600226A3 (en) | 2012-09-28 |
Family
ID=23133727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0600226A HUP0600226A3 (en) | 2001-05-30 | 2002-05-23 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use |
Country Status (9)
Country | Link |
---|---|
US (2) | US7105556B2 (hu) |
EP (1) | EP1401433B1 (hu) |
JP (1) | JP4365587B2 (hu) |
AT (1) | ATE487493T1 (hu) |
CA (1) | CA2449006A1 (hu) |
DE (1) | DE60238255D1 (hu) |
ES (1) | ES2354149T3 (hu) |
HU (1) | HUP0600226A3 (hu) |
WO (1) | WO2002096357A2 (hu) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2384194A1 (en) * | 1999-08-31 | 2001-03-08 | David P. M. Pleynet | Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
TW200300681A (en) * | 2001-11-12 | 2003-06-16 | Ono Pharmaceutical Co | Carboxylic acid derivative compound and medicament containing same as active ingredient |
EP1656368A4 (en) * | 2002-07-09 | 2009-08-26 | Bristol Myers Squibb Co | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS |
KR20050122220A (ko) * | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
US7652061B2 (en) * | 2003-05-20 | 2010-01-26 | Novartis A.G. | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1867560A (zh) * | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
US7790734B2 (en) * | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
JP2007513058A (ja) * | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102134230B (zh) * | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
WO2005118166A2 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006011397A1 (ja) * | 2004-07-27 | 2006-02-02 | Kowa Company., Ltd. | 糖尿病の予防または治療のための薬剤 |
WO2006064779A1 (ja) * | 2004-12-14 | 2006-06-22 | Shionogi & Co., Ltd. | 6’位にカルボキシを有するインドロモルヒナン誘導体 |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1906934A4 (en) * | 2005-07-14 | 2012-03-07 | Franco Folli | DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME |
WO2007014023A1 (en) * | 2005-07-21 | 2007-02-01 | Valeant Research & Development | Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv |
CA2622472C (en) | 2005-09-14 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
GEP20135791B (en) * | 2005-09-14 | 2013-03-25 | Takeda Pharmaceutical | Use of dipeptidyl peptidase inhibitors |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
WO2007112368A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
DK2073810T3 (da) * | 2006-09-13 | 2011-10-31 | Takeda Pharmaceutical | Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
EP2679224A1 (en) | 2007-08-01 | 2014-01-01 | University of Pittsburgh of the Commonwealth System of Higher Education | Nitro oleic acid modulation of type II diabetes |
PL2200606T3 (pl) | 2007-09-10 | 2018-08-31 | Janssen Pharmaceutica, N.V. | Sposób wytwarzania związków użytecznych jako inhibitory SGLT2 |
EP2280928B1 (en) | 2008-05-01 | 2018-07-25 | Complexa Inc. | Vinyl substituted fatty acids |
EP2299997A4 (en) | 2008-06-19 | 2012-01-11 | Univ Utah Res Found | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
US9066902B2 (en) | 2009-07-31 | 2015-06-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fatty acids as anti-inflammatory agents |
US8686167B2 (en) | 2009-10-02 | 2014-04-01 | Complexa, Inc. | Heteroatom containing substituted fatty acids |
SG10201500258WA (en) | 2009-10-14 | 2015-03-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
MX339252B (es) * | 2009-12-18 | 2016-05-18 | Euroscreen Sa | Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43). |
SI2568988T1 (sl) | 2010-05-11 | 2016-10-28 | Janssen Pharmaceutica N.V. | Farmacevtske formulacije, obsegajoče 1-(beta-D-glukopiranozil)-2-tienilmetilbenzenske derivate kot inhibitorje SGLT |
US20110319325A1 (en) * | 2010-06-28 | 2011-12-29 | Complexa, Inc. | Multi-component pharmaceuticals for treating diabetes |
WO2012140120A1 (en) | 2011-04-13 | 2012-10-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN112010861A (zh) | 2015-07-07 | 2020-12-01 | H.隆德贝克有限公司 | 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
US10537541B2 (en) | 2015-10-02 | 2020-01-21 | Complexa Inc. | Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid |
BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS584711B2 (ja) | 1978-08-02 | 1983-01-27 | 参天製薬株式会社 | ピロリジン誘導体 |
FR2678938B1 (fr) | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
PT1228067E (pt) | 1999-11-10 | 2004-11-30 | Takeda Chemical Industries Ltd | Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica |
-
2002
- 2002-05-22 US US10/153,342 patent/US7105556B2/en not_active Expired - Lifetime
- 2002-05-23 JP JP2002592870A patent/JP4365587B2/ja not_active Expired - Fee Related
- 2002-05-23 DE DE60238255T patent/DE60238255D1/de not_active Expired - Lifetime
- 2002-05-23 HU HU0600226A patent/HUP0600226A3/hu not_active Application Discontinuation
- 2002-05-23 ES ES02737192T patent/ES2354149T3/es not_active Expired - Lifetime
- 2002-05-23 CA CA002449006A patent/CA2449006A1/en not_active Abandoned
- 2002-05-23 AT AT02737192T patent/ATE487493T1/de not_active IP Right Cessation
- 2002-05-23 EP EP02737192A patent/EP1401433B1/en not_active Expired - Lifetime
- 2002-05-23 WO PCT/US2002/016628 patent/WO2002096357A2/en active IP Right Grant
-
2006
- 2006-04-19 US US11/406,799 patent/US7452907B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1401433A2 (en) | 2004-03-31 |
WO2002096357A3 (en) | 2003-09-25 |
ATE487493T1 (de) | 2010-11-15 |
JP2005506954A (ja) | 2005-03-10 |
EP1401433B1 (en) | 2010-11-10 |
JP4365587B2 (ja) | 2009-11-18 |
US20030092697A1 (en) | 2003-05-15 |
ES2354149T3 (es) | 2011-03-10 |
CA2449006A1 (en) | 2002-12-05 |
HUP0600226A2 (en) | 2006-11-28 |
US7105556B2 (en) | 2006-09-12 |
DE60238255D1 (de) | 2010-12-23 |
WO2002096357A2 (en) | 2002-12-05 |
US7452907B2 (en) | 2008-11-18 |
EP1401433A4 (en) | 2005-10-12 |
US20060189598A1 (en) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0600226A2 (en) | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use | |
PT1757606E (pt) | Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação | |
HK1068555A1 (en) | New formulations and use thereof | |
EP1462134A4 (en) | INSTRUMENT OF ADMINISTRATION FOR MEDICAL USE | |
IL163278A (en) | Formulations including glp-1 compounds and their use in drug preparation | |
HUP0302845A3 (en) | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical | |
HUP0400988A3 (en) | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments | |
AU1328502A (en) | Novel targeted compositions for diagnostic and therapeutic use | |
IL162095A0 (en) | Formulations for use in medical or diagnostic procedures | |
GB0119025D0 (en) | Compounds and their therapeutic use | |
TWI365187B (en) | 7-azaindoles and the use thereof as therapeutic agents | |
GB0209356D0 (en) | Medical facemask | |
GB2376943B (en) | Compounds and their therapeutic use | |
GB0112237D0 (en) | Compounds and their therapeutic use | |
GB0128122D0 (en) | Therapeutic use | |
GB0200843D0 (en) | Benzodioxinopyrroles their preparation and use | |
GB0024517D0 (en) | Use of medicaments | |
GB0123991D0 (en) | New therapeutic use | |
GB0119193D0 (en) | Medical use | |
GB0110881D0 (en) | Medical use | |
GB0105944D0 (en) | Anaesthetic Formulation | |
IL158881A0 (en) | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments | |
PL349455A1 (en) | Medical chair's platform | |
GB0201615D0 (en) | Compounds and their therapeutic use | |
GB0128512D0 (en) | Compounds and their therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC4A | Lapse of provisional application due to refusal |